Moneyta · stock research · no sign-up needed
ABBV
FollowFigures below come straight from SEC filings: every number is the company's own, on the record.
Revenue (FY FY2025)
$61.2B
Net income (Q2 FY2026)
$3.6B
as filed with the SEC
Institutions holding
4,237
+118 last quarter
Overview · AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic derm…
Management team
- Mr. Jeffrey Ryan Stewart · Executive VP & Chief Commercial OfficerFind on LinkedIn
- Mr. Timothy J. Richmond · Executive VP & Chief Human Resources OfficerFind on LinkedIn
- Dr. Azita Saleki-Gerhardt Ph.D. · Executive VP & COOFind on LinkedIn
- Mr. Scott T. Reents · Executive VP & CFOFind on LinkedIn
Start free to see the full management team.
Links open LinkedIn searches, not verified profiles. Team data from our market-data vendor's company profile.
What history says when its signals fire
Every signal Moneyta surfaces carries its full base-rate history: how often it beat the index, and how often it didn't. See the evidence
The desk's Snapshot
3 of 15 open to everyone · members see allRead the full desk report on ABBV
Seven analysts, the debate, the risk review, every claim cited. And the same for every name you hold.
Free plan, no credit card required. Silver opens the full report, $19.99 a month. AI-written · every claim cites a source · Insight, not advice.
The full desk report
Seven AI analysts read the filings and argue both sides. What survives, with every claim cited, for members.
Who holds it, who's buying Gold
Full holder table, quarter-over-quarter flows, insider transactions, and the conviction screen.
Largest holder
Net flow last quarter
Insider buys, 90d
Further reading
Source: SEC EDGAR (XBRL company facts, form 13F-HR). Educational analysis of published data: insight, not advice.